The totality of these data supports the notion that a coordinated deregulation of SCRIB, VANGL2 and NOS1AP at the gene dosage or transcription level, possibly in conjunction with other PCP protein abnormalities, may affect cancer cell behavior in a sub-type-specific manner. The gene discussed is SCRIB; the disease is cancer.